Location: Canton

120 Oakside Court

Suite H

Canton, Georgia 30114

Tel: (678) 785-9600

Fax: (877) 380-2077

The purpose of this study is to evaluate inclisiran sodium 300 mg s.c. (equivalent to 284 mg inclisiran) compared to placebo on reducing the risk of 4P-MACE in adult patients at high risk for their first major adverse cardiovascular event. Randomized participants will receive study medication (inclisiran or placebo), administered s.c. on Day 1, Day 90, then every 6 months thereafter. This is an event-driven study. Therefore, the study will continue until the required number of clinical events have occurred across both treatment arms, and all participants have a minimum of 3 years of follow-up during the double-blind treatment period.

Location(s): Canton, Jacksonville (Headquarters), Jacksonville - LaVilla (Downtown), Lake City, Macon, Southside, St. Augustine

Condition: Heart Disease

The purpose of this study is to evaluate the effect of zilebesiran on systolic and diastolic blood pressure and to characterize the pharmacodynamic (PD) effects and safety of zilebesiran as add-on therapy.

Location(s): Canton, Jacksonville (Headquarters), Jacksonville - LaVilla (Downtown), Lake City, Macon, St. Augustine

Condition: Hypertension

This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with underlying heterozygous familial hypercholesterolemia (HeFH) and/or ASCVD to evaluate the efficacy, safety, and tolerability of obicetrapib as an adjunct to diet and maximally tolerated lipid-lowering therapy.

Location(s): Canton, Jacksonville (Headquarters), Jacksonville - LaVilla (Downtown), Lake City, Macon, St. Augustine

Condition: Cholesterol, Heart Disease

MiniMedâ„¢ 780G system in adult subjects with insulin-requiring type 2 diabetes in a home setting. The combined run-in period and study period will be approximately 135 days long. At the conclusion of the 90-day study period, subjects will be given the opportunity to transition to a period of continued access. They will be allowed to continue using the study device system until further notice from Sponsor. A total of at least 300 subjects with insulin-requiring type 2 diabetes age 18-80 will be enrolled at up to 25 investigational centers across the United States, using the 780 insulin pump in combination with Guardian 4 sensor and Guardian 4 transmitter.

Location(s): Canton, Jacksonville - LaVilla (Downtown)

Condition: Diabetes

The purpose of this study is to determine the effect and safety of LY3209590 compared to degludec in adult participants with type 2 diabetes who are starting basal insulin for the first time. Additional participants will continue to be enrolled in a maximum extended enrollment cohort.

Location(s): Canton, Jacksonville - LaVilla (Downtown)

Condition: Diabetes